Still using 454?

[adaptivegenome]

Our core facility is phasing out our 454 and the same is happening at our collaborator's institution. Is this a general trend and if so, is there still interest in the development of tools to analyze 454 data?

[kmcarr]

We have no immediate plans to phase it out but our 454 service has slowed to a trickle. We have not received our FLX+ upgrade yet and frankly I doubt it will have any impact on usage. It seems to me that 454 has completely lost mind share within the community and, it appears, within Roche itself.

[Gone]

Maybe,454 will be eliminated？but we are still using this tech in some projects as auxiliary(for example,small genome,compare genome,PCR reaction analysis etc).
this year we also hope to build out our business on this tech in other countries.

[flxlex]

454 sequencing is still in demand here (Norway). Last year we had many more amplicon than shotgun projects. Now, shotgun is picking up again, perhaps due to FLX+. But, it took a long time (>6 months!) before our upgraded instrument worked again, so we are only now beginning to test FLX+ sequencing. We are getting longer and longer reads, but not yet with the peak (mode) length around 750-800 bases.

[tyfach]

We've just inherited a 454 Junior (we're a molecular pathology diagnostic lab with a dedicated R&D team) and we've been invited to participate in a multi-centre trial (amplicon deep seq), all based around 454. However, it seems to us (without being very familiar with the platform) that the relatively low-throughput/high run cost, when compared to the IonTorrent & MiSeq, make it seem like the third-choice platform to conduct the trial on - are we correct in this assumption or is there still life in the old dog yet?
Additionally, can anyone give us an up-to-date throughput/cost estimate? (we're going by 10MB / £1000).

[Gone]

We've just inherited a 454 Junior (we're a molecular pathology diagnostic lab with a dedicated R&D team) and we've been invited to participate in a multi-centre trial (amplicon deep seq), all based around 454. However, it seems to us (without being very familiar with the platform) that the relatively low-throughput/high run cost, when compared to the IonTorrent & MiSeq, make it seem like the third-choice platform to conduct the trial on - are we correct in this assumption or is there still life in the old dog yet?
Additionally, can anyone give us an up-to-date throughput/cost estimate? (we're going by 10MB / £1000).

We can offer two types services on 454,one is 16s sequencing;the another is shotgun.(including PCR,library construction and sequencing,bioinformatics analysis);By and large,the cost will be caculated by per run;it's about 14,000$ per run(not includes analysis) .